The European Association for the Study of Diabetes (EASD), the European Foundation for the Study of Diabetes (EFSD), the Chinese Diabetes Society (CDS) and Eli Lilly and Company today announced a long-term funding relationship for Chinese diabetes research. According to the World Health Organization (WHO), as of 2010, an estimated 285 million people worldwide had diabetes, 90% of whom had T2DM. Materials and Methods. They were followed up until the end of 2008. He also screened for MODY genes and found MODI mutation family in Chinese people. For each significant variable, a score was calculated by multiplying β by 100 and rounding to the nearest integer. The frequency of N9a was higher in T2DM patients compared with that in the controls (6.2% vs.
At recent years, more data support that the lipid ratios, including TC/HDL-C and LDL-C/HDL-C are more sensitive in reflecting the morbidity and severity of CVD than individual lipid levels [4–7]. In addition, there is definitely discrimination towards people with type 1 diabetes. Eli Lilly has an existing relationship with the EFSD through the company’s funding of the EFSD/Lily Diabetes Research Programme in Europe. From 1997 to 1999, he was a visiting associate professor of medicine at Harvard University. Due to the high prevalences of MetS in IFG/IGT and T2D Chinese subjects, CVD and other vascular diseases, such as stroke, should be paid attention to, and this would be a heavy burden for both individual families and the public medical service system in China. In the waiting room of a diabetes clinic in Shanghai, it’s standing-room only. The Chinese Ministry of Health has introduced large-scale diabetes awareness and education programs to address diabetes, driven by the CDS.
The guidelines summarize all the recommendations for the diagnosis and treatment of diabetes, which are based on the latest research results from China and around the world. It stands that China faces a heavy health care burden and expenditure attributable to diabetes. In light of these reports, it has been suggested that microalbuminuria screening should be added to the assessment of the cardiovascular disease risk profile, in addition to lipids and blood pressure [5, 6]. All these great achievements were carried out by my CDS president predecessors: Professor Rongli Qian, Professor Kunsan Xiang, Professor Wenying Yang and Professor Linong Ji. The scientific compilation and review processes by CDS comprised rounds of engagement from idea generation, drafting, evidence review and polishing, which took 18 months for each version, with two separate scientific review systems (editorial board and consulting committee). As a result, this class of oral anti-diabetic drugs is included among the first-line drug therapies in the China guidelines, while they are not included in the therapeutic algorithm proposed by the American Diabetes Association. The evidence of genetic determinants fueled the study to identify susceptibility genes for MetS using linkage or association studies.
But in contrast to what we saw in Brazil, Paleru Jagannivas and Sheela Krishnaswamy of the Heinz Corporation note that despite pressures on the government to strengthen its response, NGOs have essentially been ignored, while the MHSW has not tried to work with them. All these accumulated contribution from Chinese to global insights. The International Diabetes Federation (IDF) is an umbrella organization of over 230 national diabetes associations in 170 countries and territories. We did MS intervention from 2011 to 2013 for the rural community resident population aged 45 years and above in Zhoushi. 73. The combination of intracellular and extracellular electrolyte disturbances may be implicated in the pathogenesis of neuropathy, nephropathy and vascular complications in diabetic patients. Thousands of training programmes were run after each version to educate us with comprehensive modular updates.
The ‘Clinical Practice Survey Report’ revealed the real situation in the adherence of physicians to the guidelines. Also, we cannot completely exclude the possibility of selection bias but such bias may be limited given our response rates and population-based design. This is where the rubber hits the road, and all findings need to be translated into clinical practice as ‘Go with Guideline’. Continuous quality improvement with different perspectives will drive the clinical excellence of diabetes and promote the quality of diabetes care with guidance from the ‘Standards of Care for Type 2 Diabetes in China’, which worked as a benchmark of care delivery in China. The venous blood samples were drawn after 12-hour overnight fasting for examining fasting plasma glucose (FPG), serum creatinine, triglyceride (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C). We are experiencing development in economics and diabetes epidemic at the same time. The primary prevention to reduce the number of diabetes patients, the secondary prevention to decrease complications and the tertiary prevention to cut diabetes-related death all form major challenges for China.
CDS stands at the frontline of the fight against diabetes. Physical parameters, including height, weight, waist circumference, hip circumference, sitting blood pressure, and body composition were measured. From surrogate markers like HbA1c, blood pressure and low-density lipoprotein cholesterol to hard endpoints, a strong belief for incoming tipping points of clinical outcomes always motivated us to keep on going. The ‘Standards of Care for Type 2 Diabetes in China’ would definitely be updated from time to time in the future based on more knowledge on the entity of type 2 diabetes in Chinese people gained from the results in research and experiences in clinical practice in China. It would provide even more improvements in the diabetes care over China in the future. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. 1 Compilation Group of Chinese Guideline for Diabetes Prevention and Treatment (Chinese Diabetes Society).
China Guideline for Diabetes (2003 Edition). Peking University Medical Press: Beijing, 2004; 72–77. 2 Chinese Diabetes Society. A lot of people, especially young kids, are being bombarded with messages about unhealthy food. Zhonghua Yi Xue Za Zhi 2008; 88(18): 1227–1245. 3 Chinese Diabetes Society. Similar to that in Japanese patients, inadequate β-cell response to increasing insulin resistance results in loss of glycemic control and increased risk of diabetes, even with relatively little weight gain, and seems to be the main defect to the progression of the disease in Chinese patients.
Chin J Diabetes 2012; 20(1): S1–S36. 4 Chinese Diabetes Society. China Guideline For Type 2 Diabetes (2013 Edition). In addition, anthropometric measurements including height, weight, and fasting blood sugar were taken. 5Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study.
Diabetes Care 1997; 20(4): 537–44. 6Yang W, Liu J, Shan Z, et al. Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial. Lancet Diabetes Endocrinol 2014; 2(1): 46–55. 7Weng J, Li Y, Xu W, et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicenter randomised parallel-group trial. Lancet 2008; 371(9626): 1753–1760.